TG Therapeutics Inc (TGTX)
Liquidity ratios
| Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 4.59 | 3.58 | 3.62 | 5.92 | 5.53 | 2.87 | 2.93 | 3.16 | 5.02 | 4.68 | 4.43 | 5.06 | 4.24 | 5.20 | 5.78 | 6.99 | 3.35 | 4.16 | 1.39 | 1.77 |
| Quick ratio | 3.65 | 2.77 | 2.76 | 5.00 | 4.65 | 2.23 | 2.35 | 3.04 | 4.83 | 4.52 | 4.28 | 4.84 | 4.09 | 5.08 | 5.67 | 6.91 | 3.27 | 4.08 | 1.24 | 1.66 |
| Cash ratio | 2.73 | 2.00 | 2.10 | 4.05 | 3.97 | 1.99 | 2.21 | 3.04 | 4.83 | 4.52 | 4.27 | 4.81 | 4.07 | 5.07 | 5.66 | 6.91 | 3.27 | 4.08 | 1.24 | 1.66 |
TG Therapeutics Inc's liquidity ratios have shown fluctuations over the past few quarters. The current ratio has generally remained healthy, indicating that the company has ample current assets to cover its current liabilities. However, it has ranged from a low of 2.87 to a high of 6.99, with a significant spike in the most recent quarter compared to previous periods.
The quick ratio, which provides a more stringent measure of liquidity by excluding inventory from current assets, has also shown variability but has generally been at acceptable levels. It ranged from 2.23 to 6.91 over the periods analyzed, showing that the company can meet its short-term obligations without relying on inventory liquidation.
The cash ratio, which is the most conservative liquidity measure as it considers only cash and cash equivalents, has exhibited similar fluctuations. It ranged from 1.99 to 6.91, with the company holding varying levels of cash to cover its current liabilities without relying on the sale of other current assets.
Overall, TG Therapeutics Inc's liquidity position appears solid, with improving liquidity ratios in the most recent quarter. However, continued monitoring of liquidity trends is advisable to ensure the company can meet its short-term obligations effectively.
Additional liquidity measure
| Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash conversion cycle | days | 335.34 | 272.38 | 279.11 | 192.38 | 183.42 | 453.48 | 625.23 | 0.00 | 0.00 | 4.61 | 53.90 | 75.79 | 114.65 | 140.77 | 332.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
The cash conversion cycle of TG Therapeutics Inc has shown variations over the past few quarters. The cycle, which represents the time it takes for a company to convert its investments in inventory or account receivables into cash flow from sales, has ranged from as low as 4.61 days to as high as 625.23 days in recent quarters.
In the most recent quarter ended September 30, 2024, the cash conversion cycle stood at 335.34 days, indicating that TG Therapeutics took approximately 335 days to convert its investments in inventory and accounts receivable into cash. This increase from the previous quarter suggests a potential slowdown in the company's ability to convert its resources into cash efficiently.
Looking back over the past few quarters, we observe significant fluctuations in the cash conversion cycle. The cycles in the previous quarters also exhibited high numbers, with particularly notable spikes in the first quarter of 2023 and the second quarter of 2023. The company's ability to efficiently manage its working capital and convert it into cash has been inconsistent, as evidenced by the fluctuating cycle durations.
Further analysis and monitoring of TG Therapeutics Inc's cash conversion cycle trends will be crucial to assess the company's operational efficiency, liquidity management, and overall financial health. Efforts to optimize inventory management, streamline accounts receivable processes, and improve cash collection procedures may help in reducing the cycle duration and enhancing the company's cash flow position.